Corrigendum to ‘18F-FDG PET for Dementia Evaluation: Co-pathologies, New Diseases, and Its Roles in The Era of Anti-Amyloid Treatment’ (Seminars in Nuclear Medicine (2025) 55(4) (526–537), (S0001299825000571), (10.1053/j.semnuclmed.2025.04.007))
Thientunyakit T., Muangpaisan W., Minoshima S. Corrigendum to ‘18F-FDG PET for Dementia Evaluation: Co-pathologies, New Diseases, and Its Roles in The Era of Anti-Amyloid Treatment’ (Seminars in Nuclear Medicine (2025) 55(4) (526–537), (S0001299825000571), (10.1053/j.semnuclmed.2025.04.007)). Seminars in Nuclear Medicine (2025). doi:10.1053/j.semnuclmed.2025.09.001 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112449
Title
Corrigendum to ‘18F-FDG PET for Dementia Evaluation: Co-pathologies, New Diseases, and Its Roles in The Era of Anti-Amyloid Treatment’ (Seminars in Nuclear Medicine (2025) 55(4) (526–537), (S0001299825000571), (10.1053/j.semnuclmed.2025.04.007))
The authors regret that there was an error in description for Parkinson's Disease (PD) and Huntington's Disease (HD) in the table 1. So, the authors would like to have table 1 revised as follows: ‘PD: Relatively preserved metabolism in basal ganglia (caudate, putamen); possible mild frontal or occipital hypometabolism. HD: Early bilateral hypometabolism in caudate and putamen; progressive cortical hypometabolism (frontal and parietal) in later stages.’ The authors would like to apologise for any inconvenience caused.
